Radiology Medical News about non-Hodgkin lymphomas

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas - the PETAL trial
Leukemia and Lymphoma, 11/04/09

Duhrsen U et al. – In aggressive non–Hodgkin lymphomas, the result of positron emission tomography (PET) with [18F]fluorodeoxyglucose performed after a few cycles of chemotherapy has been shown to correlate with long–term treatment outcome. The PETAL trial investigates whether a change in treatment protocol may improve the outcome of patients with a positive scan after two cycles of (R–)CHOP. In patients with a positive scan, relapses were six times more frequent than in patients with a negative scan.

<< Previous
Diagnostic accuracy and potential limitations of transvaginal...

Next >>
Repeat Mammography Screening Among Unmarried Women With and...

Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09 Relevance Score: 68%

Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkins lymphoma: The Iowa Womens Health Study
International Journal of Cancer, 11/05/09 Relevance Score: 67%

Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma
Cancer Management and Research, 10/23/09 Relevance Score: 67%

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study : The Lancet Oncology
The Lancet Oncology - Online First, 10/12/09 Relevance Score: 67%

Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkins Lymphoma
Journal of Clinical Oncology, 10/08/09 Relevance Score: 67%